Bolzano

In the province of Bolzano 86% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than qu...

Full description

Bibliographic Details
Main Authors: Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
Format: Article
Language:English
Published: SEEd Medical Publishers 2012-11-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
hpv
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/452
id doaj-316448e279254e12b454aca61e42fcd6
record_format Article
spelling doaj-316448e279254e12b454aca61e42fcd62020-11-24T21:50:36ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2012-11-01132S222410.7175/fe.v13i2S.452417BolzanoRoberto Gasparini0Donatella Panatto1Bruna Dirodi2Rosa Prato3Gianni Amunni4Valter Turello5Luigi Sudano6Paolo Cristoforoni7Sara Boccalini8Paolo Bonanni9Dipartimento di Scienze della Salute, Università di GenovaDipartimento di Scienze della Salute, Università di GenovaDirezione Access to Medicine, GlaxoSmithKline, VeronaDipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di FoggiaDipartimento di Ginecologia, Perinatologia e Riproduzione Umana, Università di FirenzeDipartimento di Prevenzione U.O. Igiene e Sanità Pubblica, Azienda USL 3 GenovaAssessorato Sanità, Salute e Politiche Sociali, Servizio Igiene, Sanità Pubblica, Veterinaria e degli Ambienti di lavoroDipartimento di Oncologia Ginecologica, Istituto Nazionale per la Ricerca sul Cancro, GenovaDipartimento di Sanità Pubblica, Università di FirenzeDipartimento di Sanità Pubblica, Università di FirenzeIn the province of Bolzano 86% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 4 cases of cervicocarcinoma and 2 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (11,035 €/QALY).https://journals.seedmedicalpublishers.com/index.php/FE/article/view/452hpvvaccination strategyscreeningbolzanocost-effectiveness analysis
collection DOAJ
language English
format Article
sources DOAJ
author Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
spellingShingle Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
Bolzano
Farmeconomia: Health Economics and Therapeutic Pathways
hpv
vaccination strategy
screening
bolzano
cost-effectiveness analysis
author_facet Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
author_sort Roberto Gasparini
title Bolzano
title_short Bolzano
title_full Bolzano
title_fullStr Bolzano
title_full_unstemmed Bolzano
title_sort bolzano
publisher SEEd Medical Publishers
series Farmeconomia: Health Economics and Therapeutic Pathways
issn 2240-256X
publishDate 2012-11-01
description In the province of Bolzano 86% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 4 cases of cervicocarcinoma and 2 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (11,035 €/QALY).
topic hpv
vaccination strategy
screening
bolzano
cost-effectiveness analysis
url https://journals.seedmedicalpublishers.com/index.php/FE/article/view/452
work_keys_str_mv AT robertogasparini bolzano
AT donatellapanatto bolzano
AT brunadirodi bolzano
AT rosaprato bolzano
AT gianniamunni bolzano
AT valterturello bolzano
AT luigisudano bolzano
AT paolocristoforoni bolzano
AT saraboccalini bolzano
AT paolobonanni bolzano
_version_ 1725882867083378688